Home
>
ipos-overview
Proposed Symbol | DMIIU |
---|---|
Company Name | Drugs Made In America Acquisition II Corp. |
Exchange | NASDAQ Global |
Share Price | $10.00 |
Employees | 2 (as of 09/25/2025) |
Status | Priced |
Shares Offered | 50,000,000 |
Offer amount | $500,000,000 |
Shares Over Alloted | |
Company Address | 1 EAST BROWARD BOULEVARD SUITE 700 FORT LAUDERDALE FL 33301 |
Company Phone | 954-870-3104 |
Company Website | |
CEO | Lynn Stockwell |
State of Inc | |
Fiscal Year End | 12-31 |
Total Offering Expense | $750,000.00 |
Shareholder Shares Offered | |
Shares Outstanding | 63,700,000 |
Lockup Period (days) | 180 |
Lockup Expiration | 2026-03-24 00:00:00 |
Quiet Period Expiration | 2025-11-04 00:00:00 |
CIK | 0002040475 |
DealId | 1342770-114639 |
Drugs Made In America Acquisition II Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our “initial business combination.” To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry. We are confident that we will be able to use our individual experiences as well as our networks to achieve success. Together, we will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions. In the end, we will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion. At the same time, we will endeavor to generate excellent returns for our shareholders. --- Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.